Steen Klysner (PhD), Chief Executive Officer
Dr. Klysner has more than 25 years of experience from several executive and non-executive positions in the Biotech and Biopharmaceutical industry. This includes small as well as large players like ALK, Novo Nordisk, Pharmexa and Nordic Vaccine, most recently coming from a position as VP of preclinical R&D at Allergopharma, the Allergy business unit of Merck KGaA in Germany. His expertise is focused on management of innovative R&D processes, CMC and GMP related to the production of biologicals and vaccines, business development, strategy, partnering and communication.
Dr. Klysner originally graduated as MSc from the University of Copenhagen, followed by a PhD from the Danish Technical University and an Industrial Research degree from the Danish Academy of Technical Sciences.
Charlotte Dyring (MSc, PhD), Chief Operating Officer and co-founder
Dr. Dyring has an extensive track record in the field of protein expression in animal cells, mastering a wide range of expression systems, tools and techniques. She has substantial practical experience with upstream process development according to industry standards, including the process transfer to cGMP manufacturing. Dr. Dyring is a recognised world leading expert of the Drosophila S2 expression technology and was instrumental in the development of the technology to the current level of sophistication and robustness.
With a Chemical Engineering degree from the Technical University of Denmark (1992), Dr. Dyring subsequently received a doctoral degree in combination with an industrial research degree from DTU and the Danish Academy of Technical Sciences, respectively. She has been working in several scientific positions in the pharmaceutical and the biotechnology industry at Kabi Pharmacia (later Pharmacia & Upjohn) and Pharmexa A/S (Affitech A/S) since 1995.
Wian de Jongh (MSc PhD), Chief Scientific Officer and co-founder
Dr. de Jongh (South African) has a MSc (cum laude) in Chemical Engineering from the University of Stellenbosch, South Africa and was awarded a doctorate in Biotechnology from the Technical University of Denmark (DTU) in 2006. Furthermore, Dr. de Jongh was awarded an affiliated associate professorship at DTU in 2017.
During his PhD, Dr. de Jongh developed advanced cell line genetic engineering tools and applied metabolic engineering methodologies to cell lines with engineered improved production characteristics. Dr. de Jongh has significant experience in the pharmaceutical industry in molecular biology, cell line development, project management, upstream process development, process scale-up and process transfer to cGMP manufacturing.
He was instrumental in the development of the proprietary expression vector system ExpreS2ion Biotechnologies was founded on. Dr. de Jongh has also served on the steering committee and as project manager on several grant-funded projects.
Bent U. Frandsen (MSc), Chief Business Officer
Bent Frandsen has 23 years of professional experience in management, finance, and business development positions in multinational companies, including 19 years Life Science experience at public listed companies, Lundbeck, ALK-Abelló, Coloplast, and private companies, NsGene, CMC Biologics, and Amphidex. Bent has completed licensing, services, M&A, and new cash deals in excess of €200 million, and has furthermore been in charge of successfully closing numerous collaboration agreements pertaining to research and development of both new chemical entities and biologicals.
Bent graduated as MSc in Finance and Strategic Planning from Copenhagen Business School, Denmark, in 1993.